Abstract 4258: FL-501 is a potential best in class GDF-15 inhibitor with extended half-life and potent anti-cachexia activity in preclinical models
Year: 2025
Type: conference-abstract
Source: Cancer Research
Authors: Kelly Foster, Michael S. Haas, Walter Newman, Jason Baum, Roma Kaul
Institution: Leap Therapeutics, Inc. (United States)
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4409633602